Prophylactic human papillomavirus (HPV) vaccines represent a revolutionary approach in
preventing and potentially eliminating HPV-related cancers. Overwhelming real-life data are …

Introduction Human papillomavirus (HPV) vaccination has been proven to effectively protect
against HPV infection and infection-associated cancer. However, there are concerns about …

Background There is ongoing debate about the possible protective effect of the bivalent
human papillomavirus (2vHPV) vaccine, targeting oncogenic types HPV-16/18, against …

Objective Genital warts are the most common sexually transmitted disease and have a
detrimental impact on quality of life. Genital warts could be prevented by prophylactic HPV …

Human papillomavirus (HPV) imposes an increased risk of developing cervical, anal and
oropharyngeal cancer. In the Western world, HPV infection is currently the major cause of …

Background: Human papillomavirus (HPV) is now known to be a necessary cause of
cervical cancer, and prophylactic HPV vaccines aimed at preventing genital warts …

Background Although the human papillomavirus (HPV) vaccine has been recommended in
Germany for girls since 2007, no organised vaccination programme was introduced and …

Human papillomavirus (HPV) infections continue to be one of the most common sexually
transmitted infections worldwide. The oncogenic potential of this virus was well established …

Human papillomavirus (HPV) is a circular, double-stranded DNA virus and recognized as
the most prevalent sexually transmitted infectious agent worldwide. The HPV life cycle …

Background Vaccines have been demonstrated to protect against high-risk human
papillomavirus infection (HPV), including HPV-16/18, and cervical lesions among HIV …